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We present a pilot validation study performed on 10 
European Union (EU) Member States, of a point preva-
lence survey (PPS) of healthcare-associated infections 
(HAIs) and antimicrobial use in Europe in 2011 involv-
ing 29 EU/European Economic Area (EEA) countries 
and Croatia. A total of 20 acute hospitals and 1,950 
patient records were included in the pilot study, which 
consisted of validation and inter-rater reliability (IRR) 
testing using an in-hospital observation approach. In 
the validation, a sensitivity of 83% (95% confidence 
interval (CI): 79–87%) and a specificity of 98% (95% 
CI: 98–99%) were found for HAIs. The level of agree-
ment between the primary PPS and validation results 
were very good for HAIs overall (Cohen’s κappa (κ): 
0.81) and across all the types of HAIs (range: 0.83 for 
bloodstream infections to 1.00 for lower respiratory 
tract infections). Antimicrobial use had a sensitivity 
of 94% (95% CI: 93–95%) and specificity of 97% (95% 
CI: 96–98%) with a very good level of agreement (κ: 
0.91). Agreement on other demographic items ranged 
from moderate to very good (κ: 0.57–0.95): age (κ: 
0.95), sex (κ: 0.93), specialty of physician (κ: 0.87) 
and McCabe score (κ: 0.57). IRR showed a very good 
level of agreement (κ: 0.92) for both the presence of 
HAIs and antimicrobial use. This pilot study suggested 
valid and reliable reporting of HAIs and antimicrobial 
use in the PPS dataset. The lower level of sensitivity 
with respect to reporting of HAIs reinforces the impor-
tance of training data collectors and including valida-
tion studies as part of a PPS in order for the burden of 
HAIs to be better estimated. 
Introduction
In 2011, the European Centre for Disease Prevention 
and Control (ECDC) initiated the first European point 
prevalence survey (PPS) of HAIs and antimicrobial use 
in acute care hospitals [1] involving 29 European Union 
(EU)/ European Economic Area (EEA) countries and 
Croatia. The objective was to estimate the total burden 
(prevalence) of HAIs and antimicrobial use in European 
acute care hospitals.
A pilot validation study was undertaken in the first 
phase of this PPS in 2011 with two major objectives: 
(i) to test the sensitivity and specificity of reporting 
HAIs and antimicrobial use and the level of agree-
ment between primary and validation data collectors, 
whereby this constituted the validation component of 
the study; (ii) to test the inter-rater reliability (IRR) of 
hospital data collectors across Europe.
This paper focuses on the aggregated results for sev-
eral EU Member States of this pilot validation study. 
Ten EU Member States took part in the validation com-
ponent (Bulgaria, Finland, Germany, Hungary, Italy, 
Latvia, Lithuania, Poland, Spain, United Kingdom) 
and eight of these countries in the IRR component 
(Bulgaria, Finland, Germany, Italy, Lithuania, Poland, 
Spain, United Kingdom).
Method
The sample size for the pilot study was calculated to 
produce validation results overall for the European 
PPS rather than at individual country specific level. A 
pilot ECDC PPS had indicated a prevalence of 7.1% and 
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an average hospital size of 300 beds [2]. The sample 
size for the pilot validation study was calculated at 
approximately 2,000 patients for an estimated sensi-
tivity of reporting HAIs of 80% with a precision of +/- 
5% and a prevalence of 7% [3,4]. These 2,000 patients 
were specified by the ECDC validation pilot protocol as 
approximately 200 patients per country within the 10 
participating countries, sampled in at least two hospi-
tals per country.
Two approaches, including a validation method by an 
external validation team (method 1) and an on-site 
assessment of the IRR of different hospital PPS data 
collectors (method 2), were taken in order to address 
the objectives. The methods are summarised here and 
a full description is available in the ECDC pilot valida-
tion protocol [4].
Validation
A standard ECDC protocol was used by all countries 
[3]. Each country collected data on 100 patient records 
from each of two hospitals. The hospitals and the 
patient records were chosen by the national coordina-
tors from each country and not randomly allocated at 
a country level. A number of approaches were taken 
including retrospective, simultaneous same day, simul-
taneous same time, blind and unblind data collection. 
The approach undertaken by each country was pur-
posively selected dependent on timing of the primary 
PPS and availability of resources. Countries also had 
an option of oversampling within the protocol, whereby 
the number of HAIs in the validation sample was 
increased on purpose to increase the precision of the 
specificity estimation, by selecting wards with higher 
prevalence (e.g. intensive care units) in blind validation 
or by including all HAI cases detected in the primary 
PPS in unblind validation.
The validation findings were considered the ‘gold 
standard’ (true positives and true negatives) as the 
validation team consisted of at least one trained expert 
from (and/or acting on behalf of) the national/regional 
PPS coordinating centre (external to the validated hos-
pital), using the ECDC-PPS protocol and codebook [5] 
and accompanied by a hospital staff member for the 
purposes of access and orientation.
Identical data to the primary data collector were col-
lected by the validator using one or more of the 
approaches outlined above. Patient notes, nursing 
notes, hospital information systems and clinical ward 
personal were the data sources used.
From the validation dataset, the positive predic-
tive value (PPV) was calculated as the percentage of 
patients with true HAIs (or patients receiving antimi-
crobials as appropriate) among all positive patients in 
the primary dataset, and the negative predictive value 
(NPV) as the percentage of true negative cases among 
all patients identified as negative in the primary sam-
ple. The results of the validation were applied to the 
aggregated primary data by multiplying the number of 
all positive cases in the primary sample by the PPV to 
obtain an approximation of the number of true posi-
tives to account for potential differences in prevalence 
due to oversampling. The same procedure was per-
formed for negative cases with the NPV. This allowed 
determination of the sensitivity and specificity for the 
primary sample [4,6]. 95% confidence intervals (CI) 
were calculated using a continuity-corrected version 
of the Wilson’s score method. They were evaluated as 
‘worst case’ instances using a combination method. 
The effects of omitting these adjustments, in most 
cases did not result in major differences to the results 
presented here.
On site assessment of inter-rater reliability
Five HAI-positive and 10 HAI-negative patient records 
were selected from a single setting, i.e. intensive care 
unit (ICU), where the prevalence of infection was the 
highest, or, if access to the ICU was restricted, in a 
limited number of other wards with expected high HAI 
prevalence, such as high dependency units.
Between two and five hospital primary PPS data col-
lectors gathered data at an agreed time in the selected 
ward/setting in turn with the national contact point 
(validator). A procedure was followed to minimise any 
potential bias inclusive of the other rater(s) waiting in 
another room or at a distance where the reproducibility 
process could not be heard (e.g. use music in the wait-
ing room/area). Data items were collected as detailed in 
method 1 and agreement between the data collections 
was analysed using kappa (κ) statistics (0.81–1.00 is 
very good, 0.61–0.80 is good, 0.41–0.60 is moder-
ate, 0.21–0.40 is fair/marginal, < 0.2 is poor; negative 
values are possible and also denote ‘poor’ agreement 
[7-9]. κ statistics were also reported for certain vari-
ables of the validation approach (method 1), as it can 
be argued that the external validation team does not 
truly represent a gold standard for HAIs and variables 
such as the McCabe score.
Results
Validation
The primary data set that originated from the 20 hospi-
tals in the 10 participating countries comprised 3,958 
patient records. Among these, the prevalence of HAIs 
was 9% (367 patients) and the prevalence of antimicro-
bial use was 38% (1,504 patients). Validation data were 
collected from October to December 2011. Of the 3,958 
primary patient records, a total of 1,950 were selected 
for validation in accordance with the calculated study 
sample size. Of those, 1,912 were matched to the pri-
mary dataset, since it was not possible to link all patient 
records due to errors in data entry or missing data. The 
reported prevalence of HAIs in the matched validation 
dataset was 12% (233 patients) and the prevalence of 
antimicrobial use was 46% (878 patients). Due to over-
sampling in the validation dataset, the prevalence of 
HAIs in this dataset was significantly higher than in 
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the ‘primary’ set, Χ2(1) = 7.7, p = 0.005. The prevalence 
of antimicrobial use was also higher in the validation 
dataset, Χ2(1) = 27.5, p < 0.001. Four of the ten countries 
included oversampling.
There was 97% agreement (κ = 0.81) between primary 
records and the validation records for the presence of 
an HAI (Table 1). The level of agreement was very good 
across all the most important types of HAIs, ranging 
from κ = 0.83 for bloodstream infections to κ =1.00 for 
lower respiratory tract infections (Table 2). Specificity 
of reporting HAIs was 98% (95% CI: 98–99%) with sen-
sitivity comparatively lower at 83% (95% CI: 79–87%) 
(Table 1). The sensitivity by type of HAI ranged from 
83% for bloodstream infections to 100% for lower res-
piratory tract infections, with specificity values higher 
than 99% for all types of HAI (Table 2).
Very good results (96% agreement, k=0.91) were 
achieved with respect to the recording of overall anti-
microbial use (Table 3). Sensitivity and specificity 
were both very high at 94% (95% CI: 92.9–95.3%) and 
97% (95% CI: 96.1–97.5%) respectively. Validation of 
the route of antimicrobial administration oral, paren-
teral showed that oral antimicrobials were frequently 
reported as parenteral, resulting in a lower specificity 
for the parental route and a lower sensitivity for the 
oral route (Table 4).
At the individual variable level, some variation was 
noted. Agreement on basic demographic variables 
was very good: age (κ=0.95), sex (κ=0.93), specialty of 
physician (κ=0.87). A high level of agreement was also 
found with respect to the presence of invasive devices, 
although specificity for the presence of peripheral vas-
cular catheters (93%; 95% CI: 91–95%) was noted to be 
significantly lower than that of central venous cathe-
ters (99%; 95% CI: 98–99%). Variables which required 
more interpretation such as McCabe score had a mod-
erate score (κ = 0.57).
Inter-rater reliability
Eight of ten countries participated in the IRR component 
of the pilot study with a total of 44 raters across all the 
participating hospitals, rating 195 patient records. An 
analysis of IRR by selected variables was undertaken 
on the dataset. Variables were selected on the basis 
of their importance and the frequency of reporting in 
the dataset. Analysis of IRR overall showed a very good 
level of agreement (κ = 0.92) for both the presence of 
HAIs (96%) and antimicrobial use (97%) (Table 5). 
There was very good IRR (κ > 0.8) for most of the PPS 
variables (with the exception of HAI origin) (κ =0.31).
Discussion
Studies on validation of national HAI surveillance 
are rarely published, and when they are, a variety of 
approaches are described, according to a recent review 
in the United States (US) [10]. In that review, of those 
that included either a validation or an IRR study, the 
results were varied, underscoring the need for PPS 
to include validation studies to add confidence to 
Table 1
Validation of the point prevalence survey for assessing healthcare-associated infections, 10 European Union Member States, 
2011
A. Validation of the point prevalence survey (n=1,912 patient records)
Validation data
Healthcare-associated infection No healthcare-associated infection Total
Primary data
Healthcare-associated infection 193 40 233
No healthcare-associated infection 29 1,650 1,679
Total 222 1,690 1,912
Positive predictive value (PPV): 193/233 = 82.8%; negative predictive value (NPV): 1,650/1,679 = 98.3%.
B. Results of the validation study applied to the total primary point prevalence survey (n=3,958 patient records)
Validation data
Healthcare-associated infection No healthcare-associated infection Total
Primary data
Healthcare-associated infection 304a 63 367
No healthcare-associated infection 62 3,529b 3,591
Total 366 3,592 3,958
Sensitivity: 304/366*100 = 83.1%; specificity: 3,529/3,592*100 = 98.2%.
The 10 European Union Member States that took part in the validation part of the study were Bulgaria, Finland, Germany, Hungary, Italy, 
Latvia, Lithuania, Poland, Spain, United Kingdom.
a 304 = PPV*367.
b 3,529 = NPV*3,591.
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Table 2
Validation of the point prevalence survey for healthcare-associated infections (HAIs), by type of HAI, 10 European Union 
Member States, 2011 (n=1,912 patient records)a 







All HAIs 233 83.1 (78.7–86.7) 98.2 (97.7–98.6) 82.8 (77.4–87.4) 98.3 (97.5–98.8) 0·81 
Bloodstream infections 12 83.3 (50.9–97.1) 99.9 (99.6–100) 83.3 (51.6–97.9) 99.9 (99.6–100) 0.83
Gastrointestinal infections 13 92.9 (64.2–99.6) 100 (99.7–100) 100 (75.3–100) 99.9 (99.7–100) 0.96
Lower respiratory tract 
infections 5 100 (46.3–100) 100 (99.7–100) 100 (47.8–100) 100 (99.8–100) 1.00
Pneumonia 52 95.9 (89.3–98.7) 99.9 (99.7–100) 95.9 (89.9–98.9) 99.9 (99.6–100) 0.96
Surgical site infections 56 98.2 (89.2–99.9) 99.9 (99.7–100) 98.2 (90.4–100) 99.9 (99.7–100) 0.98
Urinary tract infections 27 92.6 (74.2–98.7) 99.9 (99.6–100) 92.6 (75.7–99.1) 99.9 (99.6–100) 0.93
CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value.
The 10 European Union Member States that took part in the validation part of the study were Bulgaria, Finland, Germany, Hungary, Italy, 
Latvia, Lithuania, Poland, Spain, United Kingdom.
a Number of patient records used for validation, which could be matched to those reported in the primary point prevalence survey data.
b 95% CIs have been adjusted to the overall prevalence among the primary cases (9%).
Table 3
Validation of the point prevalence survey for assessing antimicrobial use, 10 European Union Member States, 2011
A. Validation of the point prevalence survey (n=1,912 patient records)
Validation data
Antimicrobial No antimicrobial Total
Primary data
Antimicrobial 833 45 878
No antimicrobial 37 997 1,034
Total 870 1,042 1,912
Positive predictive value (PPV): 833/878 = 94.9%; negative predictive value (NPV): 997/1,034 = 96.4%.
B. Results of the validation study applied to the total primary point prevalence survey (n=3,958 patient records)
Validation data
Antimicrobial No antimicrobial Total
Primary data
Antimicrobial 1,427a 77 1,504
No antimicrobial 88 2,366b 2,454
Total 1,515 2,443 3,958
Sensitivity: 1,427/1,515*100 =94.2%; specificity; 2,366/2,443*100 = 96.8%.
The 10 European Union Member States that took part in the validation part of the study were Bulgaria, Finland, Germany, Hungary, Italy, 
Latvia, Lithuania, Poland, Spain, United Kingdom.
a 1,427 = PPV*1,504.
b 2,366 = NPV*2,454.







Patients on antimicrobials 878 94.2 (92.9–95.3) 96.8 (96.1–97.5) 94.9 (93.2–96.2) 96.4 (95.1–97.5) 0.91
Parenteral route 843 97.3 (95.9–98.3) 88.6 (84.4–91.9) 95.8 (94.3–97.1) 92.5 (88.9–95.3) 0.87
Oral route 281 88.2 (83.8–91.5) 97.6 (96.3–98.5) 92.9 (89.2–95.6) 95.9 (94.4–97.1) 0.87
CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value.
The 10 European Union Member States that took part in the validation part of the study were Bulgaria, Finland, Germany, Hungary, Italy, 
Latvia, Lithuania, Poland, Spain, United Kingdom.
a Number of patient records used for validation, which could be matched to those reported in the primary point prevalence survey data.
b 95% CIs have been adjusted to the overall prevalence among the primary cases (38%).
Table 4
Validation of the point prevalence survey for antimicrobial use, by administration route, 10 European Union Member 
States, 2011 (n=1,912 patient records)a
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interpretation of the data. This study is the first multi-
country validation study undertaken on the first ECDC 
PPS dataset. Based on the findings, a revised protocol 
for data validation of the PPS of HAIs and antimicrobial 
use in European acute care hospitals was made avail-
able in 2012. This protocol might be helpful to other 
countries considering similar studies in the future [4].
The validation component identified an overall sensi-
tivity of 83% (95% CI: 79–87%) and specificity of 98% 
(95% CI: 98–99%) for the presence of HAI. The level of 
agreement between the primary analysis and the vali-
dation assessment was very good across all the types 
of HAI. Previous studies indicated some variation at the 
level of individual types of HAI. In these studies respir-
atory tract infections had lower sensitivity, specificity 
and inter-rater reliability than other types of HAI [11-
13]. However, the results of this pilot study indicated a 
high level of specificity and a high level of agreement 
for these types of HAIs. It is likely that the training 
given to support ECDC PPS has had an impact on the 
good validity results in our pilot study, however, this is 
difficult to assess and, to our knowledge, no study has 
been published to date assessing the effect of training 
on data validity. Moreover, the relatively good sensitiv-
ity and specificity results found in our pilot study may 
have been influenced by the ‘experimental’ conditions 
(e.g. selection of two hospitals per country willing to 
participate), which may have resulted in higher sen-
sitivity and specificity than would have been found in 
validation across a non-selected group of hospitals. 
Indeed, in four national validation surveys carried out 
in 2012 during the second phase of the ECDC PPS, the 
average sensitivity of reporting HAIs was 71.9%, con-
siderably lower in our pilot study [1]. The sensitivity 
(83%) in our study indicates potential underreporting 
of HAIs in the ECDC PPS. This underreporting of HAIs 
may have resulted from difficulties with application of 
definitions or availability of patient record information 
at the time of data collection. To the authors’ knowl-
edge, this was the first study which formally validated 
the reporting of antimicrobial use within a PPS study. 
Antimicrobial use had a high sensitivity of 94% (95% 
CI: 93–95%) and specificity of 97% (95% CI: 96–98%) 
with a very good level of agreement. Validation of the 
route of antimicrobial showed that oral antimicrobials 
were frequently reported as parental antimicrobials.
Other variables within the validation dataset were well 
recorded. A complex patient records review study by 
Yawn and Wollan (2005) [14] found that demographic 
data that required copying explicit information (e.g. 
sex, birth date), ‘free-text’ data that required identify-
ing and copying (e.g. chief complaints and diagnoses), 
and data that required abstractor judgment in deter-
mining what to record (e.g. whether heart disease was 
considered) differed in terms of rates of agreement. In 
our study, agreement between the validation and the 
primary data collectors on more basic demographic 
variables ranged from moderate for the McCabe score 
to very good for sex and age. This finding was in line 
with the scarce literature published to date [11-12,15-
19], wherein basic demographic variables such as age 
and sex tend to have very good levels of agreement 
compared to those variables where interpretation is 
required, such as the McCabe score or other markers 
of co-morbidity. The variables requiring abstractor 
judgment in this pilot validation study usually involved 
verification with a clinician present on the ward, which 
may account for the higher than expected validity.
The IRR component showed that the in-hospital IRR 
reliability was very good, for HAIs and antimicrobial 
use. This level of agreement was also found for other 
variables with the notable exception of HAI origin, 
which had a fair/marginal κappa. No studies that have 
looked formally at IRR in more than one country were 
identified in the literature. One study [17] did exam-
ine the difference between teams of data collectors 
within an Indonesian PPS and indicated that inter-
observer variation differed significantly between the 
teams of data collectors in terms of completeness of 
data, and most importantly in the number of detected 
HAIs. Differences of note in this previous study were 
with respect to surgical site infection, urinary tract 
infection and septicaemia (p = 0.01) and the reported 
agreement (κ) did not exceed 0.59 for any type of HAI 
[17]. Their evaluation indicated that ascertainment was 
affected by underreporting in patient records, and the 
retrospective nature of data collection for validation 
purposes.
Variable Numbera Agreement rate Kappa
HAI present 202 96% 0.92
Pneumonia 133 100% 1.00
Other lower respiratory 
infection 133 100% 1.00
Antimicrobial use 217 97% 0.92
Fluoroquinolone use 254 97% 1.00
Oral route 253 99% 0.95
Parental route 253 99% 0.94
Surgical prophylaxis 253 99% 0.93
Device present 93 96% 0.81
HAI origin 91 96% 0.31
HAI: healthcare-associated infection.
The eight European Union Member States that took part in inter-
rater reliability part of the study were Bulgaria, Finland, Germany, 
Italy, Lithuania, Poland, Spain, United Kingdom.
a Number of variables recorded for all patients; one patient can 
have more than one HAI.
Table 5
Inter-rater reliability results by selected variables, 
pilot validation study of a point prevalence survey on 
healthcare-associated infections and antimicrobial use, 
eight European Union Member States, 2011 (n=44 raters 
and 195 patient records)
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While the issue of record keeping with respect to device 
use, infection criteria and antimicrobial use, had been 
identified as a potential limitation at the outset of this 
study, the outcomes in the validation aspects of this 
pilot study were better than expected in this regard. 
The IRR results overall in this pilot study were better 
than those published previously in the literature with 
respect to presence of HAIs and types of HAI.
As with all observation studies of this nature there are 
a number of potential biases which are acknowledged 
herein. The first of these is the potential for selection 
bias as participating countries chose the hospitals and 
patient records; these were not randomly allocated at a 
country level. Observer bias potential is also acknowl-
edged as not all the validators were blinded to the pri-
mary results although the high levels of IRR indicate 
minimal risk of this.
In summary, this pilot study suggested that the ECDC 
PPS dataset of HAIs and antimicrobial use was valid 
and reliable. Basic demographic data and antimicro-
bial use data had very good levels of validity and reli-
ability and may not need to be routinely collected in 
future validation studies. The high specificity and IRR 
are an indication that the training on the case defini-
tions organised during preparation of the ECDC PPS 
was effective. The lower sensitivity findings show the 
potential for underreporting of HAIs in the ECDC PPS 
and highlight the importance of validation studies for 
future surveillance activities in order for the burden of 
HAI to be better estimated.
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